首页> 外文期刊>Jornal Brasileiro de Pneumologia >Combined pulmonary fibrosis and emphysema: an increasingly recognized condition.
【24h】

Combined pulmonary fibrosis and emphysema: an increasingly recognized condition.

机译:合并肺纤维化和肺气肿:一种日益被认可的疾病。

获取原文
           

摘要

Combined pulmonary fibrosis and emphysema (CPFE) has been increasingly recognized in the literature. Patients with CPFE are usually heavy smokers or former smokers with concomitant lower lobe fibrosis and upper lobe emphysema on chest HRCT scans. They commonly present with severe breathlessness and low DLCO, despite spirometry showing relatively preserved lung volumes. Moderate to severe pulmonary arterial hypertension is common in such patients, who are also at an increased risk of developing lung cancer. Unfortunately, there is currently no effective treatment for CPFE. In this review, we discuss the current knowledge of the pathogenesis, clinical characteristics, and prognostic factors of CPFE. Given that most of the published data on CPFE are based on retrospective analysis, more studies are needed in order to address the role of emphysema and its subtypes; the progression of fibrosis/emphysema and its correlation with inflammation; treatment options; and prognosis.
机译:文献中越来越多地认识到合并肺纤维化和肺气肿(CPFE)。 CPFE患者通常是重度吸烟者或以前吸烟者,胸部HRCT扫描时伴有下叶纤维化和上叶肺气肿。尽管肺活量检查显示肺体积相对保留,但它们通常会出现严重的呼吸困难和低DLCO。在这类患者中,中度至严重的肺动脉高压很常见,他们患肺癌的风险也增加。不幸的是,目前尚无有效的CPFE治疗方法。在这篇综述中,我们讨论了CPFE的发病机理,临床特征和预后因素的最新知识。鉴于大多数关于CPFE的已发表数据都是基于回顾性分析的,因此需要更多的研究来探讨肺气肿及其亚型的作用。纤维化/肺气肿的进展及其与炎症的关系;治疗选择;和预后。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号